The Asia Pacific non-alcoholic steatohepatitis market is expected to reach US$ 4,040.30 million by 2028 from US$ 216.54 million in 2021. The market is estimated to grow at a CAGR of 51.9% from 2021 to 2028.

The rising prevalence of Non-Alcoholic Steatohepatitis is expected to grow the opportunities for research & development of Non-Alcoholic Steatohepatitis diagnostics and management in developing nations. Leading market players increased their penetration across emerging markets by growing their distribution networks and augmented manufacturing capabilities. Emerging markets in India and South Korea are expected to offer potential growth opportunities for crucial non-alcoholic steatohepatitis (NASH) manufacturers in the coming years due to the large patient population; high prevalence of lifestyle diseases, such as obesity, diabetes, low HDL cholesterol, high lipids, and high blood pressure; increasing disposable income; improving healthcare infrastructure; and growing medical tourism in the above-mentioned countries. Asia Pacific is a business-friendly and adaptable hub due to relatively less stringent regulations and data requirements. The Asia Pacific non-alcoholic steatohepatitis market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Non-Alcoholic Steatohepatitis Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Non-Alcoholic Steatohepatitis Market Segmentation

The Asia Pacific non-alcoholic steatohepatitis market is segmented into product, application, sales channel, and country. Based on product type, the Asia Pacific non-alcoholic steatohepatitis market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period.Based on application, the Asia Pacific non-alcoholic steatohepatitis market is segmented into treatment and diagnosis. The treatment segment dominated the Asia Pacific non-alcoholic steatohepatitis market in 2020. Based on sales channel, the Asia Pacific non-alcoholic steatohepatitis market is segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment dominated the Asia Pacific non-alcoholic steatohepatitis market in 2020. Based on country, the Asia Pacific non-alcoholic steatohepatitis market is segmented into China, Japan, India, Australia, South Korea, Rest of Asia-Pacific. China dominated the Asia Pacific non-alcoholic steatohepatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the Asia Pacific non-alcoholic steatohepatitis market

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Non-Alcoholic Steatohepatitis Market – By Product
1.3.2 APAC Non-Alcoholic Steatohepatitis Market – By Application
1.3.3 APAC Non-Alcoholic Steatohepatitis Market – By Sales Channel
1.3.4 APAC Non-Alcoholic Steatohepatitis Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Non-Alcoholic Steatohepatitis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific PEST Analysis
4.3 Experts Opinion
5. APAC Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of NASH
5.1.2 Increasing Initiatives for the Awareness of NASH
5.2 Market Restraints
5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH
5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH
5.3 Market Opportunities
5.3.1 Growing Opportunities in Developing Nations
5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.4 Future Trends
5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.5 Impact Analysis
6. Non-alcoholic steatohepatitis (NASH) Market– APAC Analysis
6.1 APAC Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
7. APAC Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product
7.1 Overview
7.2 Product Market Revenue and Forecast Analysis (US$ Mn)
7.3 Vitamin E and Pioglitazone
7.3.1 Overview
7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)
7.4 Ocaliva
7.4.1 Overview
7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)
7.5 Elafibranor
7.5.1 Overview
7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)
7.6 Selonsertib & Cenicriviroc
7.6.1 Overview
7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)
8. APAC Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application
8.1 Overview
8.2 Application Market Revenue and Forecast Analysis (US$ Mn)
8.3 Treatment
8.3.1 Overview
8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diagnosis
8.4.1 Overview
8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)
9. APAC Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel
9.1 Overview
9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.5 Online Provider
9.5.1 Overview
9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)
10. APAC Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis
10.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecasts To 2028
10.1.1 Overview
10.1.3 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)
10.1.3.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.1.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.1.2 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.1.3.1.3 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.1.3.1.4 China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.2.1 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.2.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.1.3.2.3 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.1.3.2.4 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.3 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.3.1 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.3.2 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.1.3.3.3 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.1.3.3.4 India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.4.1 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.4.2 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.1.3.4.3 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.1.3.4.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.5 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.5.1 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.5.2 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.1.3.5.3 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.1.3.5.4 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.6 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.6.1 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.6.2 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.1.3.6.3 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.1.3.6.4 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Cadila Pharmaceuticals Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Intercept Pharmaceuticals, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Novartis AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Galmed Pharmaceuticals.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GENFIT.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Siemens Healthineers AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Laboratory Corporation of America Holdings
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms

LIST OF TABLES

Table 1. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 2. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 3. China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 4. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 5. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 6. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 8. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 9. India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 10.   Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 11.   Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 12.   Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 13.   South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 14.   South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 15.   South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 16.   Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 17.   Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 18.   Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 19.   Organic Developments Done By Companies
Table 20.   Inorganic Developments Done By Companies
Table 21.   Glossary of Terms
 
 

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Non-Alcoholic Steatohepatitis market forecast.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Non-Alcoholic Steatohepatitis market forecast, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the non-alcoholic steatohepatitis, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies – Asia Pacific Non-Alcoholic Steatohepatitis Market

● Cadila Pharmaceutical.
● Intercept Pharmaceutical.
● Novartis AG.
● Galmed Pharmaceutical.
● GENFIT.
● Siemens Healthineers AG.
● Laboratory Corporation of America Holdings.